Pulmonary Disease clinical trials

Explore recruiting pulmonary disease clinical trials.

Recruiting pulmonary disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pulmonary Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Denmark, Sweden, Poland, Estonia, Portugal, Latvia +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

Germany, Netherlands, Italy, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Germany, Romania, Greece, Norway, Netherlands, Poland +4 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Romania, Lithuania, Hungary, Spain, Bulgaria, Ireland +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE)

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

STOP-COPD Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Pulmonary Disease trials by city

Pulmonary Disease in Toronto Pulmonary Disease in Vancouver Pulmonary Disease in Montreal Pulmonary Disease in Calgary Pulmonary Disease in Edmonton Pulmonary Disease in Ottawa Pulmonary Disease in Winnipeg Pulmonary Disease in Quebec City Pulmonary Disease in Hamilton Pulmonary Disease in Kitchener Pulmonary Disease in London Pulmonary Disease in Halifax Pulmonary Disease in New York Pulmonary Disease in Los Angeles Pulmonary Disease in Chicago Pulmonary Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease